GlassScriptPhysician profile
Sonia Panjwani
NPI 1316978075
$2,142.90
in general payments reported to CMS, 2019-2025
24 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $193 · 2021: $363 · 2022: $349 · 2023: $283 · 2024: $536 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.08 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $305.41 | 2020-2025 | Airsupra, Breztri |
| Amgen INC. | $291.00 | 2020-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $213.86 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Abbott Laboratories | $170.74 | 2021-2022 | |
| Genzyme Corporation | $125.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.60 | 2021-2024 | |
| Pfizer INC. | $92.47 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $60.82 | 2019-2020 | |
| Radius Health, INC. | $53.73 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.06 | 2022 | |
| Gilead Sciences, INC. | $37.89 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.48 | 2021 | |
| Corcept Therapeutics | $33.03 | 2025 | Korlym |
| Novo Nordisk INC | $32.24 | 2022-2023 | Rybelsus, Ozempic |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $32.09 | 2023 | Arexvy |
| Abbvie INC. | $24.87 | 2020 | |
| Dexcom, INC. | $24.19 | 2023 | Dexcom G6 Transmitter |
| Pharmaessentia USA Corporation | $23.49 | 2023 | Besremi |
| Novartis Pharmaceuticals Corporation | $20.44 | 2019 | |
| Eisai INC. | $19.01 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.54 | 2019 | |
| Metacel Pharmaceuticals LLC | $16.79 | 2023 | Ozobax |
| Sanofi Pasteur INC. | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Panjwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.